Lancet Rheumatology

Article	Citations
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	298
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study	241
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine	218
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study	215
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021	191
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	176
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	153
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout	135
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial	134
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	132
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study	130
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	126
COVID-19 vasculitis and novel vasculitis mimics	125
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	122
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study	118
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment	115
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study	111
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases	99
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study	98
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative	96
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study	91
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses	84
Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study	83
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?	82
Viral arthritis and COVID-19	74

Perspective of patients with autoimmune diseases on COVID-19 vaccination	74
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study	72
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform	69
Flare of rheumatoid arthritis after COVID-19 vaccination	67
Too long to wait: the impact of COVID-19 on elective surgery	66
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study	65
First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection	64
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial	64
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19	63
68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study	61
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies	61
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study	57
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial	56
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Ear	56
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study	55
Reactivation of IgA vasculitis after COVID-19 vaccination	54
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases	53
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platf	51
Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	50
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials	49
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis	45
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study	45
Adult-onset Still's disease after mRNA COVID-19 vaccine	43
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	41
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases	40
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study	39
First manifestation of adult-onset Still's disease after COVID-19	39
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial	39
COVID-19 cytokine storm: targeting the appropriate cytokine	38
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure	38
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort s	37
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	37
Adult-onset Still's disease following COVID-19 vaccination	37
Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study	37
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial	36
COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study	36
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus	36
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial	35
Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study	35
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study	35
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses	34
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study	34
The role of antirheumatics in patients with COVID-19	34
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study	33
Arthritis after SARS-CoV-2 infection	33
Hydroxychloroquine in the prevention of COVID-19 mortality	33
Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial	33
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a popul	32
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort stud	32
Cutaneous vasculitis following COVID-19 vaccination	31

Tocilizumab for severe COVID-19 pneumonia – Authors' reply	31
Inflammatory myositis after ChAdOx1 vaccination	31
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controll	31
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	30
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial	30
Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study	29
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	29
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease	29
The global epidemic of low back pain	29
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry	28
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial	28
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	28
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	27
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study	27
Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study	27
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials	27
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2	27
Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, rando	26
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	26
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised,	26
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study	26
Serious postoperative complications and reoperation after carpal tunnel decompression surgery in England: a nationwide cohort analysis	26
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients	26
Divergent effects of acute versus chronic glucocorticoids in COVID-19	26
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study	26
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study	25
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	25
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study	24
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study	23
Non-steroidal anti-inflammatory drug use in COVID-19	23
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial	23
Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective	22
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease	22
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre	22
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases	21
Current issues in rheumatoid arthritis-associated interstitial lung disease	21
Type I interferon, anti-interferon antibodies, and COVID-19	21
How long do revised and multiply revised knee replacements last? A retrospective observational study of the National Joint Registry	21
The STAR care pathway for patients with pain at 3 months after total knee replacement: a multicentre, pragmatic, randomised, controlled trial	21
Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study	20
Remotely delivered cognitive behavioural and personalised exercise interventions for fatigue severity and impact in inflammatory rheumatic diseases (LIFT): a multicentre, randomised, controlled, open-	20
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a p	20
How long do revised and multiply revised hip replacements last? A retrospective observational study of the National Joint Registry	20
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study	19
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19	19
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	19
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial	19
Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study	19
Clinical and molecular associations with outcomes at 2 years after acute knee injury: a longitudinal study in the Knee Injury Cohort at the Kennedy (KICK)	19
Therapeutic implications of ongoing alveolar viral replication in COVID-19	19
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/	18
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort	17
Incident systemic rheumatic disease following COVID-19	17
Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage	17
Clinician-reported outcome measures in lupus trials: a problem worth solving	17
The influence of sex hormones on musculoskeletal pain and osteoarthritis	16
Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study	16
Global, regional, and national burden of neck pain, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	16
Patients with gout: an under-recognised group at high risk of COVID-19	16
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases	16
Systemic sclerosis in the time of COVID-19	16
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study	16
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-contro	16
MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study	16
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials	15
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab	15
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	15
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study	15
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	15
Large language models and rheumatology: a comparative evaluation	14
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	14
Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases	14
Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy	14
Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomis	14
Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records	14
Prediction models for the risk of total knee replacement: development and validation using data from multicentre cohort studies	13
FDA approval for anifrolumab in patients with lupus	13
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period	13
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled sub	13
Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis	13

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre,	12
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis	12
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19	12
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial	12
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY	12
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies	12
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study	12
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases	12
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study	12
Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	12
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study	12
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease	12
Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis	11
Immunosuppression and SARS-CoV-2 breakthrough infections	11
Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19	11
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study	11
Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination	11
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials	11
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH	11
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	11
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study	11
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	11
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	11
Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma	11
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?	10
Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?	10
Who, what, and when—effective therapy for severe COVID-19	10
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial	10
Mental health before and during the pandemic in people with systemic sclerosis	10
Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study	10
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	10
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY	10
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial	10
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study	10
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	10
New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?	10
Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City	10
Research priorities to reduce the impact of musculoskeletal disorders: a priority setting exercise with the child health and nutrition research initiative method	10
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	10
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	10
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial	9
The efficacy and safety of targeting GM-CSF in arthritis	9
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	9
No perfect therapy for the imperfect COVID-19 cytokine storm	9
The opening salvo of anti-complement therapy against COVID-19	9
Monkeypox associated acute arthritis	9
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	9
Gender representation on editorial boards of rheumatology journals	9
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases	9
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	9
Barriers to translational research in Sjögren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease	9
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases	9
Shared genetic susceptibility between trigger finger and carpal tunnel syndrome: a genome-wide association study	9
Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders	9
Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial	9
Women in rheumatology in Africa	9
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	8
Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial	8
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	8
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine	8
Research priority setting for paediatric rheumatology in the UK	8
Defining the scourge of COVID-19 hyperinflammatory syndrome	8
Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice	8
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study	8
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS coh	8
Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium's international and multidisciplinary consensus recommendations	7
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts	7
Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic	7
Interpreting big-data analysis of retrospective observational data	7
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicent	7
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinat	7
Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial	7
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial	7
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist	7
Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series	7
A shared basis for overlapping immunopathologies in giant cell arteritis and polymyalgia rheumatica	7
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	7
Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs	7
Temporal trends in adverse pregnancy outcomes in axial spondyloarthritis in Sweden: a cohort study	7
JAK inhibitors: fate in doubt for rheumatoid arthritis?	7
What does endemic COVID-19 mean for the future of rituximab?	7
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	7
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	7
Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline	7
Sulfasalazine: a risk factor for severe COVID-19?	6
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longit	6
Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls	6
Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis	6
COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups	6
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study	6
The global burden of osteoarthritis: past and future perspectives	6
Impact of methotrexate on first-dose COVID-19 mRNA vaccination	6
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	6
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know	6
Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts	6